Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence.

Brody AL, London ED, Olmstead RE, Allen-Martinez Z, Shulenberger S, Costello MR, Abrams AL, Scheibal D, Farahi J, Shoptaw S, Mandelkern MA.

Psychiatry Res. 2010 Sep 30;183(3):218-24. doi: 10.1016/j.pscychresns.2009.06.004. Epub 2010 Aug 3.

2.

Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette.

Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, Costello MR, Farahi J, Saxena S, Monterosso J, London ED.

Neuropsychopharmacology. 2009 Jan;34(2):282-9. doi: 10.1038/npp.2008.87. Epub 2008 Jun 18.

3.

Negative association of pretreatment cigarette use with smoking-induced striatal dopamine release in smokers receiving bupropion treatment.

Weinstein AM, Freedman N, Greif J, Yemini Z, Mishani E, London E, Chisin R, Bocher M.

Am J Addict. 2016 Sep;25(6):486-92. doi: 10.1111/ajad.12419. Epub 2016 Jul 28.

PMID:
27467186
4.

Smoking-induced ventral striatum dopamine release.

Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, Lee GS, Huang J, Hahn EL, Mandelkern MA.

Am J Psychiatry. 2004 Jul;161(7):1211-8.

PMID:
15229053
5.

Effect of a history of major depressive disorder on smoking-induced dopamine release.

Brody AL, Olmstead RE, Abrams AL, Costello MR, Khan A, Kozman D, Saxena S, Farahi J, London ED, Mandelkern MA.

Biol Psychiatry. 2009 Nov 1;66(9):898-901. doi: 10.1016/j.biopsych.2009.06.011. Epub 2009 Jul 29.

6.

Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.

Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S, Zamora-Paja E, Farahi J, Saxena S, London ED, McCracken JT.

Arch Gen Psychiatry. 2006 Jul;63(7):808-16.

8.

Dopaminergic activity in depressed smokers: a positron emission tomography study.

Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA.

Synapse. 2009 Aug;63(8):681-9. doi: 10.1002/syn.20646.

9.

Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.

Brody AL, Mukhin AG, Stephanie Shulenberger, Mamoun MS, Kozman M, Phuong J, Neary M, Luu T, Mandelkern MA.

Neuropsychopharmacology. 2013 Jul;38(8):1548-56. doi: 10.1038/npp.2013.53. Epub 2013 Feb 21.

10.

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS.

JAMA. 2002 Jul 24-31;288(4):468-74.

PMID:
12132977
11.

Measuring cigarette smoking-induced cortical dopamine release: A [¹¹C]FLB-457 PET study.

Wing VC, Payer DE, Houle S, George TP, Boileau I.

Neuropsychopharmacology. 2015 May;40(6):1417-27. doi: 10.1038/npp.2014.327. Epub 2014 Dec 15.

12.

Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study.

Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, Jarvik ME, London ED.

Psychiatry Res. 2004 Apr 30;130(3):269-81. Erratum in: Psychiatry Res. 2004 Dec 15;132(2):183-4.

13.

Effects of treatment for tobacco dependence on resting cerebral glucose metabolism.

Costello MR, Mandelkern MA, Shoptaw S, Shulenberger S, Baker SK, Abrams AL, Xia C, London ED, Brody AL.

Neuropsychopharmacology. 2010 Feb;35(3):605-12. doi: 10.1038/npp.2009.165. Epub 2009 Oct 28.

14.

Decreasing amphetamine-induced dopamine release by acute phenylalanine/tyrosine depletion: A PET/[11C]raclopride study in healthy men.

Leyton M, Dagher A, Boileau I, Casey K, Baker GB, Diksic M, Gunn R, Young SN, Benkelfat C.

Neuropsychopharmacology. 2004 Feb;29(2):427-32.

15.

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R.

Nicotine Tob Res. 2007 Aug;9(8):821-33. Erratum in: Nicotine Tob Res. 2007 Nov;9(11):1243.

16.

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.

Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J.

Nicotine Tob Res. 2001 May;3(2):131-40.

PMID:
11403727
17.

GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans.

Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB.

Synapse. 1999 Sep 15;33(4):268-73.

PMID:
10421707
18.

Voxelwise lp-ntPET for detecting localized, transient dopamine release of unknown timing: sensitivity analysis and application to cigarette smoking in the PET scanner.

Kim SJ, Sullivan JM, Wang S, Cosgrove KP, Morris ED.

Hum Brain Mapp. 2014 Sep;35(9):4876-91. doi: 10.1002/hbm.22519. Epub 2014 Apr 3.

19.

Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans.

Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK.

Neuropsychopharmacology. 2007 Feb;32(2):450-7. Epub 2006 Nov 8.

20.

Supplemental Content

Support Center